FDA Logo links to FDA home page
U.S. Food and Drug Administration
HHS Logo links to Department of Health and Human Services website

FDA Home Page | Dockets Home Page | Dockets Contacts and Location | Operating Status

horizonal rule

Dockets Management

Dockets Entered On April 26, 2007
Docket # Title
1978N-0038 Sunscreen Drug Products
1983V-0151 LASER LIGHT SHOW
1995S-0158 Community Disclosure of Institutional Review Boards
1995S-0316 75-Day Premarket Notifications for New Dietary Ingredients
2000P-1602 Remove Unapproved Children's Fluoride Supplements from Mkt
2003D-0044 Reporting Results for Studies Evaluating Diagnostic Tests
2005N-0272 Irradiation in the Production, Processing, and Handling of Food
2005N-0279 Food Labeling; Gluten-Free Labeling of Foods
2005P-0411 Seeking FDA Actions to Counter Flagrant Violations of the Law by Pharmacies Compounding Bio-Identical Hormone Replacement Therapy Drugs
2006D-0480 Guidance for Industry on Complementary and Alternative Medicine Products and Their Regulation by the Food and Drug Administration
2006P-0394 Revise the labeling requirements for eggs sold in the United States
2006P-0405 Require full prescribing information of all antiepileptic drugs contain specific language under Warnings or Warnings and Precautions
2006P-0428 Combivent (ipratropium bromide and albuterol sulfate)
2006P-0442 Determine that Wyeth Pharmaceuticals, Inc. discontinued its previously-approved formulation of the Reference Listed Drug Zosyn (piperacillin and tazobactam for injection), 40.5 gram pharmacy bulk via
2006P-0445 Determine if Mivacron (mivacurium chloride injection) was withdrawn for safety or efficacy reasons
2006P-0446 ANDA for PHENERGAN Promethazine Hydrochloride Suppositories USP, 12.5 mg and 25 mg
2006P-0450 Revoke approval of Allergan's supplemental NDA #21-257/S-013 for Lumigan (bimatoprost ophthalmic solution 0.03%) and deny Alcon's supplemental NDA for Travatan (travopr
2007A-0164 Request for Advisory Opinion for an Mobilecare Monitor System 2100
2007N-0051 Safety of Fresh Produce; Public Hearings
2007N-0121 Use of Medication Guides to Distribute Drug Risk Information to Patients; Public Hearing
2007P-0070 Make fluoride a prescription drug for use in tooth application, tooth paste, and in bottled water
1978N-0038 Sunscreen Drug Products
C 613 Premiere Center for Cosmetic Surgery Vol #: 150
C 614 Hillsborough County Florida Vol #: 150
C 615 State of New York, Albany Vol #: 150
1983V-0151 LASER LIGHT SHOW
VRA 11 FDA/CDRH to Precision Projection Systems, Inc Vol #: 1
1995S-0158 Community Disclosure of Institutional Review Boards
SUP 51 Immediate Trial, INC 70376, Milwaukee, Wisconsin Vol #: 56
1995S-0316 75-Day Premarket Notifications for New Dietary Ingredients
RPT 376 Louis Montgomery Enterprises Vol #: 297
2000P-1602 Remove Unapproved Children's Fluoride Supplements from Mkt
LET 3 FDA/CDER to J Kelly Vol #: 1
LET 4 FDA/CDER to J Kelly Vol #: 1
2003D-0044 Reporting Results for Studies Evaluating Diagnostic Tests
EC 5 DHL Vol #: 1
2005N-0272 Irradiation in the Production, Processing, and Handling of Food
C 15 J. Resnick Vol #: 1
C 16 M. & G. Krieger Vol #: 1
2005N-0279 Food Labeling; Gluten-Free Labeling of Foods
C 721 Food Marketing Institute Vol #: 35
C 722 U. S. A. Rice Federation Vol #: 35
C 723 Food Products Association Vol #: 35
C 724 L. Block Vol #: 35
C 725 Glutino U. S. A. Vol #: 35
C 726 International Wheat Gluten Association Vol #: 35
C 727 International Wheat Gluten Association Vol #: 35
C 728 Coastal Counseling Clinic Vol #: 35
C 729 The Vinegar Institute Vol #: 35
C 730 Association des Amldenniers et Foculiers Vol #: 35
C 731 Celiac Sprue Association U. S. A., Inc. Vol #: 35
C 732 T. Sullivan Vol #: 35
C 733 S. Tolley Vol #: 35
C 734 China SPS Enquiry Point, AQSIQ Vol #: 35
C 735 F. Tibbits Vol #: 35
C 736 C. Adams Vol #: 35
C 737 International Wheat Gluten Association Vol #: 35
EC 1962 Mrs. Nadine Marx Vol #: 31
EC 1963 Mrs. Laurie Anderson Vol #: 31
EC 1964 Ms. Amber Brenzikofer Vol #: 31
EC 1965 Ms. Huberta Yaron Vol #: 31
EC 1966 Ms. Jerilyn Ingram Vol #: 31
EC 1967 Mrs. PATRICIA KACZMAREK Vol #: 31
EC 1968 Dr. Joan Chase Vol #: 31
EC 1969 Healthy Villi-CSA/USA Vol #: 31
2005P-0411 Seeking FDA Actions to Counter Flagrant Violations of the Law by Pharmacies Compounding Bio-Identical Hormone Replacement Therapy Drugs
C 18301 Kilgore Eye Care Center Vol #: 198
2006D-0480 Guidance for Industry on Complementary and Alternative Medicine Products and Their Regulation by the Food and Drug Administration
EMC 176 J. Malsin Vol #: 7
EMC 177 L. Solin Vol #: 7
EMC 178 L. Solin Vol #: 7
EMC 179 M. Martin Vol #: 7
EMC 180 S. Hallihan Vol #: 7
EMC 181 S. Parker Vol #: 7
EMC 182 K. Carmody Vol #: 7
EMC 183 S. Sherman Vol #: 7
EMC 184 C. Eisenberg Vol #: 7
EMC 185 C. Wright Vol #: 7
EMC 186 E. Rice Vol #: 7
EMC 187 J. Wearmouth Vol #: 7
EMC 188 S. Supernovich Vol #: 7
EMC 189 M. Burk Vol #: 7
EMC 190 C. Haynes Vol #: 7
EMC 191 V. Reed Vol #: 7
EMC 192 C. Haynes Vol #: 7
EMC 193 C. Haynes Vol #: 7
EMC 194 R. Renee Vol #: 7
EMC 195 M. Barakadyn Vol #: 7
EMC 196 P. Kuczera Vol #: 7
EMC 197 J. Woodruff Vol #: 7
EMC 198 L. Ehrichs Vol #: 7
EMC 199 J. Cabanis-Brewin Vol #: 7
EMC 200 L. LeBlanc Vol #: 7
EMC 201 P. Robison Vol #: 7
EMC 202 S. Costello Vol #: 7
EMC 203 Z. Wells Vol #: 7
EMC 204 R. Elloitt Vol #: 7
EMC 205 C. Hess Vol #: 7
EMC 206 A. Vick Vol #: 7
EMC 207 S. French Vol #: 7
EMC 208 S. Spencer Vol #: 7
EMC 209 S. Howard Vol #: 7
EMC 210 J. Hord Vol #: 7
EMC 211 F. Rinard-Hord Vol #: 7
EMC 212 G. Lesher Vol #: 7
EMC 213 G. Poole Vol #: 9
EMC 214 M. Hord Vol #: 9
EMC 215 G. Sampson Vol #: 9
EMC 216 J. Kuntz Vol #: 9
EMC 217 P. Newcomer Vol #: 9
EMC 218 T. Gregory Vol #: 9
EMC 219 N. Hord Vol #: 9
EMC 220 K. McDonald Vol #: 9
EMC 221 C. Krause Vol #: 9
EMC 222 K. Reagan Vol #: 9
EMC 223 D. Silverman Vol #: 9
EMC 224 N. Brewer Vol #: 9
EMC 225 L. Nalberczinski Vol #: 9
EMC 226 T. Charlton Vol #: 9
EMC 227 D. Goldstein Vol #: 9
EMC 228 S. Yeager Vol #: 9
EMC 229 J. Lord Vol #: 9
EMC 230 M. Chaddock Vol #: 9
EMC 231 B. Martinez-Kuster Vol #: 9
EMC 232 B. Byrne Vol #: 9
EMC 233 Z. McCollum Vol #: 9
EMC 234 S. David Vol #: 9
EMC 235 K. Hunter Vol #: 9
EMC 236 S. Whittemore Vol #: 9
EMC 237 J. Ross Vol #: 9
EMC 238 L. Walker Vol #: 9
EMC 239 S. Burks Vol #: 9
EMC 240 D. Richardson Vol #: 9
EMC 241 D. Berg Vol #: 9
EMC 242 S. Morrison Vol #: 9
EMC 243 N. Gremm Vol #: 9
EMC 244 S. Morris Vol #: 9
EMC 245 L. Salvage Vol #: 9
EMC 246 N. Gordon Vol #: 9
EMC 247 M. Obsidiana Vol #: 9
EMC 248 A. Olivieri Vol #: 9
EMC 249 C. Estrada Vol #: 9
EMC 250 J. Severt Vol #: 9
EMC 251 M. Edwards Vol #: 9
EMC 252 A. Kennedy Vol #: 9
EMC 253 N. Olivieri Vol #: 9
EMC 254 G. Schmidt Vol #: 9
EMC 255 C. McCarthy Vol #: 9
EMC 256 D. Torrance Vol #: 9
EMC 257 J. Butler Vol #: 9
EMC 258 B. Telford Vol #: 9
EMC 259 M. Morrison Vol #: 9
EMC 260 J. Coronado Vol #: 9
EMC 261 M. Haskell Vol #: 9
EMC 262 L. Merck Vol #: 9
EMC 263 E. Chuan-Riley Vol #: 9
EMC 264 P. Nussbaum Vol #: 9
EMC 265 J. Kesich Vol #: 9
EMC 266 R. Haywood Vol #: 9
EMC 267 R. Singer Vol #: 9
EMC 268 T. Singleton Vol #: 9
EMC 269 C. Finn Vol #: 9
EMC 270 C. Bubny Vol #: 9
EMC 271 S. Broderick Vol #: 9
EMC 272 M. Smith Vol #: 9
EMC 273 C. Wilson Vol #: 9
EMC 274 R. Hill Vol #: 9
EMC 275 L. Francis Vol #: 9
EMC 276 B. Boyer Vol #: 9
EMC 277 K. Jones Vol #: 9
EMC 278 L. Lovestar Vol #: 9
EMC 279 B. Rosenzweig Vol #: 9
EMC 280 V. Ruskovoloshin Vol #: 9
EMC 281 D. Blackwood Vol #: 9
EMC 282 J. d'Amecourt Vol #: 9
2006P-0394 Revise the labeling requirements for eggs sold in the United States
C 87 G. Schumacher Vol #: 7
C 88 Little Art Theatre Vol #: 7
2006P-0405 Require full prescribing information of all antiepileptic drugs contain specific language under Warnings or Warnings and Precautions
C 2 Minnesota House of Representatives Vol #: 2
2006P-0428 Combivent (ipratropium bromide and albuterol sulfate)
LET 1 FDA/CDER to Boehringer Ingelheim Pharmaceuticalws Inc Vol #: 2
2006P-0442 Determine that Wyeth Pharmaceuticals, Inc. discontinued its previously-approved formulation of the Reference Listed Drug Zosyn (piperacillin and tazobactam for injection), 40.5 gram pharmacy bulk via
LET 1 FDA/CDER to Orchid Healthcare Vol #: 1
2006P-0445 Determine if Mivacron (mivacurium chloride injection) was withdrawn for safety or efficacy reasons
LET 1 FDA/CDER to Regulus Pharmaceutical Consulting Inc Vol #: 1
2006P-0446 ANDA for PHENERGAN Promethazine Hydrochloride Suppositories USP, 12.5 mg and 25 mg
LET 1 FDA/Taro Pharmaceuticals USA Inc Vol #: 1
2006P-0450 Revoke approval of Allergan's supplemental NDA #21-257/S-013 for Lumigan (bimatoprost ophthalmic solution 0.03%) and deny Alcon's supplemental NDA for Travatan (travopr
LET 1 FDA/CDER to Pfizer Inc Vol #: 2
2007A-0164 Request for Advisory Opinion for an Mobilecare Monitor System 2100
ACK 1 FDA/DDM to AFrame Digital, Inc Vol #: 1
AP 1 AFrame Digital, Inc Vol #: 1
2007N-0051 Safety of Fresh Produce; Public Hearings
C 7 L-3 Pulse Sciences Vol #: 1
C 8 Path Trace Vol #: 1
TS 1 Centers for Disease Control and Prevention Vol #: 1
TS 2 Cemter for Food Safety and Applied Nutrition Vol #: 1
TS 3 University of California, Davis Vol #: 1
TS 4 FDA/ Center for Food Sfaety and Applied Nutrition Vol #: 1
TS 5 FDA/ Office of Regulatory Affairs Vol #: 1
2007N-0121 Use of Medication Guides to Distribute Drug Risk Information to Patients; Public Hearing
EAPE 109 Evelyn, Brenda Vol #: 1
2007P-0070 Make fluoride a prescription drug for use in tooth application, tooth paste, and in bottled water
C 1 C. Weber Vol #: 1

Page created on April 26, 2007 ue

horizonal rule

Dockets Home| Dockets Contacts and Location | Operating Status | Item Code Definitions | Federal Register
FDA Home Page | Search FDA Site | A-Z Index | Contact FDA | Privacy | Accessibility

FDA/Dockets Management